RT Journal Article SR Electronic T1 Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.29.20162701 DO 10.1101/2020.07.29.20162701 A1 Philippa M. Wells A1 Katie J. Doores A1 Simon Couvreur A1 Rocio Martinez Nunez A1 Jeffrey Seow A1 Carl Graham A1 Sam Acors A1 Neophytos Kouphou A1 Stuart J.D. Neil A1 Richard S. Tedder A1 Pedro M. Matos A1 Kate Poulton A1 Maria Jose Lista A1 Ruth E. Dickenson A1 Helin Sertkaya A1 Thomas J.A. Maguire A1 Edward J. Scourfield A1 Ruth C. E. Bowyer A1 Deborah Hart A1 Aoife O’Bryne A1 Kathyrn J.A. Steel A1 Oliver Hemmings A1 Carolina Rosadas A1 Myra O. McClure A1 Joan Capedevilla-pujol A1 Jonathan Wolf A1 Sebastien Ourselin A1 Matthew A. Brown A1 Michael H. Malim A1 Tim Spector A1 Claire J. Steves YR 2020 UL http://medrxiv.org/content/early/2020/07/30/2020.07.29.20162701.abstract AB Background Understanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms.Methods We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million.Findings We demonstrated a seroprevalence of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive.Interpretation Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response.Funding NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRCCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a COVID urgent response grant from the Chronic Disease Research Foundation (CDRF).Zoe Global Limited developed the app with the guidance of clinicians. Investigators received support from the Wellcome Trust, the MRC/BHF, Alzheimers Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in partnership with KCL. This work was supported by Zoe Global. The Department of Twin Research receives grants from the Wellcome Trust (212904/Z/18/Z) and Medical Research Council/British Heart Foundation Ancestry and Biological Informative Markers for Stratification of Hypertension (AIMHY MR/M016560/1) and support from the European Union, the Chronic Disease Research Foundation (CDRF), Zoe Global the NIHR Clinical Research Facility and the Biomedical Research Centre (based at Guys and St Thomas NHS Foundation Trust in partnership with Kings College London). Kings Together Rapid COVID-19 Call awards to MHM, KJD, SJDN and RMN. MRC Discovery Award MC/PC/15068 to SJDN KJD and MHM. RST-UKRI/MRC award to RT (MC_PC_19078). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the study was granted by NHS North West - Liverpool East Research Ethics Committee (REC reference 19/NW/0187), IRAS ID 258513, and all participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request to TwinsUK.